Zobrazeno 31 - 40
of 392
pro vyhledávání: '"Lianchun Xiao"'
Autor:
Milind Javle, Robert A. Wolff, Shubham Pant, Kanwal Raghav, Ahmed Shalaby, Kavitha Reddy, Priya Bhosale, Anaemy Danner De Armas, Lianchun Xiao, Shalini Makawita, Rachna T. Shroff, Sunyoung Lee
Supplementary Figure from Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d3a5df53829e8987ae7943e68d4a786
https://doi.org/10.1158/1078-0432.22487568.v1
https://doi.org/10.1158/1078-0432.22487568.v1
Autor:
Marina Konopleva, Deborah Thomas, Linda J. Bendall, Jan Burger, Susan O'Brien, Elias Jabbour, Keith A. Baggerly, Wenbin Liu, Lianchun Xiao, Rebecca Garris, Mary Ann Richie, Hongbo Lu, Zhihong Zeng, Kirk S. Culotta, Jordan Basnett, Jitesh D. Kawedia, Michael E. Rytting, Jorge Cortes, Farhad Ravandi, Hagop Kantarjian, Yanis Boumber, Naval Daver
Supplementary Figure 1.Baseline 4EBP1 and outcomes.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88a3fb5dac71e24005574aacaac26243
https://doi.org/10.1158/1078-0432.22461071
https://doi.org/10.1158/1078-0432.22461071
Autor:
Marina Konopleva, Deborah Thomas, Linda J. Bendall, Jan Burger, Susan O'Brien, Elias Jabbour, Keith A. Baggerly, Wenbin Liu, Lianchun Xiao, Rebecca Garris, Mary Ann Richie, Hongbo Lu, Zhihong Zeng, Kirk S. Culotta, Jordan Basnett, Jitesh D. Kawedia, Michael E. Rytting, Jorge Cortes, Farhad Ravandi, Hagop Kantarjian, Yanis Boumber, Naval Daver
Purpose: Previous studies suggest a potential therapeutic role for mTOR inhibition in lymphoid malignancies. This single-center phase I/II study was designed to test the safety and efficacy of the mTOR inhibitor everolimus in combination with HyperCV
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55c21e2b130f76e3c54bb4dc8dd58094
https://doi.org/10.1158/1078-0432.c.6524687.v1
https://doi.org/10.1158/1078-0432.c.6524687.v1
Autor:
Marina Konopleva, Deborah Thomas, Linda J. Bendall, Jan Burger, Susan O'Brien, Elias Jabbour, Keith A. Baggerly, Wenbin Liu, Lianchun Xiao, Rebecca Garris, Mary Ann Richie, Hongbo Lu, Zhihong Zeng, Kirk S. Culotta, Jordan Basnett, Jitesh D. Kawedia, Michael E. Rytting, Jorge Cortes, Farhad Ravandi, Hagop Kantarjian, Yanis Boumber, Naval Daver
Supplementary Figure 2. OS and EFS by salvage status.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34a9856941391766b07a436ca73e4eef
https://doi.org/10.1158/1078-0432.22461068
https://doi.org/10.1158/1078-0432.22461068
Autor:
George A. Calin, Muller Fabbri, Michael J. Keating, Gabriel Lopez-Berestein, Anil K. Sood, Hagop M. Kantarjian, Ignacio I. Wistuba, Massimo Negrini, Ioana Berindan-Neagoe, Ramana V. Davuluri, Tara M. Lichtenberg, William Plunkett, Robert Orlowski, Alessandra Ferrajoli, M. James You, Xuemei Wang, Steliana Calin, Lynne Abruzzo, Dino Amadori, Chad V. Pecot, Vivian R. Ruvolo, Peter P. Ruvolo, Antonino Neri, Fortunato Morabito, Manuela Ferracin, Rajesha Rupaimoole, Vianey Gonzalez-Villasana, Simona Rossi, Milena S. Nicoloso, Xinna Zhang, Lucilla D'Abundo, Roxana S. Redis, Ivan Vannini, Lianchun Xiao, Enrique Fuentes-Mattei, Cristian Rodriguez-Aguayo, Cristina Ivan, Tetsuro Setoyama, Francesca Fanini, Katrien Van Roosbroeck
Dose-response curves for MEC1 and MEC2 cells treated with fludarabine.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::729d3e93129e8324c66a9f8449d875f2
https://doi.org/10.1158/1078-0432.22463100.v1
https://doi.org/10.1158/1078-0432.22463100.v1
Autor:
Razelle Kurzrock, Sadakatsu Ikeda, Funda Meric-Bernstam, James C. Yao, Robert A. Wolff, Kanwal P.S. Raghav, Abedul Haque, Bhawana George, Kenna R. Mills-Shaw, AmirAli Talasaz, Richard B. Lanman, Kimberly C. Banks, Asif Rashid, Manal M. Hassan, Hesham M. Amin, Jeffrey Morris, Lianchun Xiao, Wei Qiao, Roberto Carmagnani Pestana, Marc Uemura, Reham Abdel-Wahab, Kian H. Lim, Andrea G. Bocobo, Benjamin Tan, Robin K. Kelley, Shiraj Sen, Nora S. Sánchez, Ahmed O. Kaseb
Supplementary Figure 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55b1682427880f6f646b9a3d72e5e9a2
https://doi.org/10.1158/1078-0432.22471145
https://doi.org/10.1158/1078-0432.22471145
Autor:
Christopher Logothetis, Patricia Troncoso, Eleni Efstathiou, Gary E. Gallick, Theocharis Panaretakis, Mark A. Titus, Sumankalai Ramachandran, Guocan Wang, Sue-Hwa Lin, Nora M. Navone, Shixia Huang, Kimal Rajapakshe, Cristian Coarfa, Ana M. Aparicio, Shi-Ming Tu, Sumit K. Subudhi, Amado J. Zurita, Lianchun Xiao, Graciela M. Nogueras-Gonzalez, Miao Zhang, Paul G. Corn
Purpose:Cabozantinib, an oral inhibitor of c-MET/VEGFR2 signaling, improved progression-free survival (mPFS) but not overall survival (OS) in metastatic castrate-resistant prostate cancer. We evaluated cabozantinib plus androgen deprivation therapy (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ba5e827f18be49a85477896607d21a1
https://doi.org/10.1158/1078-0432.c.6529356
https://doi.org/10.1158/1078-0432.c.6529356
Autor:
George A. Calin, Muller Fabbri, Michael J. Keating, Gabriel Lopez-Berestein, Anil K. Sood, Hagop M. Kantarjian, Ignacio I. Wistuba, Massimo Negrini, Ioana Berindan-Neagoe, Ramana V. Davuluri, Tara M. Lichtenberg, William Plunkett, Robert Orlowski, Alessandra Ferrajoli, M. James You, Xuemei Wang, Steliana Calin, Lynne Abruzzo, Dino Amadori, Chad V. Pecot, Vivian R. Ruvolo, Peter P. Ruvolo, Antonino Neri, Fortunato Morabito, Manuela Ferracin, Rajesha Rupaimoole, Vianey Gonzalez-Villasana, Simona Rossi, Milena S. Nicoloso, Xinna Zhang, Lucilla D'Abundo, Roxana S. Redis, Ivan Vannini, Lianchun Xiao, Enrique Fuentes-Mattei, Cristian Rodriguez-Aguayo, Cristina Ivan, Tetsuro Setoyama, Francesca Fanini, Katrien Van Roosbroeck
Supplementary Table S1 Clinical characteristics of two chronic lymphocytic leukemia patient datasets; Supplementary Table S2 Clinical characteristics of two lung cancer patient datasets; Supplementary Table S3 Clinical characteristics of the ALL data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54a261c8be858a08c4414cecdb1b1973
https://doi.org/10.1158/1078-0432.22463082
https://doi.org/10.1158/1078-0432.22463082
Autor:
George A. Calin, Muller Fabbri, Michael J. Keating, Gabriel Lopez-Berestein, Anil K. Sood, Hagop M. Kantarjian, Ignacio I. Wistuba, Massimo Negrini, Ioana Berindan-Neagoe, Ramana V. Davuluri, Tara M. Lichtenberg, William Plunkett, Robert Orlowski, Alessandra Ferrajoli, M. James You, Xuemei Wang, Steliana Calin, Lynne Abruzzo, Dino Amadori, Chad V. Pecot, Vivian R. Ruvolo, Peter P. Ruvolo, Antonino Neri, Fortunato Morabito, Manuela Ferracin, Rajesha Rupaimoole, Vianey Gonzalez-Villasana, Simona Rossi, Milena S. Nicoloso, Xinna Zhang, Lucilla D'Abundo, Roxana S. Redis, Ivan Vannini, Lianchun Xiao, Enrique Fuentes-Mattei, Cristian Rodriguez-Aguayo, Cristina Ivan, Tetsuro Setoyama, Francesca Fanini, Katrien Van Roosbroeck
Purpose: The oncogenic miR-155 is upregulated in many human cancers, and its expression is increased in more aggressive and therapy-resistant tumors, but the molecular mechanisms underlying miR-155-induced therapy resistance are not fully understood.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73318acfb8913a0fa3095a7fc1d8d8f0
https://doi.org/10.1158/1078-0432.c.6525306.v1
https://doi.org/10.1158/1078-0432.c.6525306.v1
Autor:
Razelle Kurzrock, Sadakatsu Ikeda, Funda Meric-Bernstam, James C. Yao, Robert A. Wolff, Kanwal P.S. Raghav, Abedul Haque, Bhawana George, Kenna R. Mills-Shaw, AmirAli Talasaz, Richard B. Lanman, Kimberly C. Banks, Asif Rashid, Manal M. Hassan, Hesham M. Amin, Jeffrey Morris, Lianchun Xiao, Wei Qiao, Roberto Carmagnani Pestana, Marc Uemura, Reham Abdel-Wahab, Kian H. Lim, Andrea G. Bocobo, Benjamin Tan, Robin K. Kelley, Shiraj Sen, Nora S. Sánchez, Ahmed O. Kaseb
Supplemental table 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::104c59dd7c233fd7681da1036f6e7e86
https://doi.org/10.1158/1078-0432.22471160
https://doi.org/10.1158/1078-0432.22471160